CroíValve Appoints Jaime Wheeler as CEO to Advance Heart Valve Innovation

As COO, Lucy O'Keeffe will work closely with Jaime Wheeler to help CroíValve develop better treatments for tricuspid regurgitation (TR), a heart valve disease.

Jaime Wheeler has more than 25 years of experience in the healthcare industry. Before joining CroíValve, she served as Senior Vice President of Global Clinical Affairs, Transcatheter Heart Valves at Edwards Lifesciences, where she helped bring several innovative heart therapies to the market.

Bernard Collins, Chairman of CroíValve, commented: “Jaime brings a proven track record in guiding innovative technologies to market, along with leading high-performing teams. Her leadership will be hugely beneficial in guiding the company through its commercialization journey ahead as we expand our US base and global activities. I would like to thank Lucy, on behalf of the board of directors, for her dedication in leading CroíValve successfully through development and initial clinical validation, demonstrating the value proposition of the DUO System.”

Jaime Wheeler, newly appointed CEO, commented: “What drew me to CroíValve is the caliber of the team and the strength of the science behind the DUO System. I've built my career on bringing challenging, innovative technologies to patients, and I'm looking forward to doing that here, for our investors and, more importantly, for the patients living with tricuspid regurgitation."

Lucy O’Keeffe, newly appointed COO, former CEO and Board member, added: “As CroíValve looks towards commercialization, it is the appropriate time to bring in a leader with the right experience for this next phase. Jaime’s exceptional track record of successfully bringing novel transcatheter devices to market is a tremendous asset for CroíValve. I am thrilled to collaborate with her as we embark on this exciting next chapter, accelerating our mission to deliver the DUO System to the patients who need it most.”

CroíValve is a medical device company that is developing a new minimally invasive heart valve treatment for tricuspid regurgitation (TR). The company's research, development, and operations are based in Ireland, while its clinical and regulatory teams are based in the United States.

The company's DUO™ System is still being tested and is currently an investigational medical device. It has not yet been approved for sale or commercial use in any country.

Read Also- Perceptual Robotics Secures £4M+ Funding to Scale Autonomous Wind Turbine Inspections